Replies to post #7300 on Revance Therapeutics Inc (RVNC)

[TimelessGoblin26]

I think Galderma also reported QoQ growth.

They sounded pretty optimistic on RHA in Q2, but probably helped by new product launch.

[Emannow]

Up 7% quarter over quarter Daxi unit growth is amazing! Botox was down -17% quarter over quarter!

In Q4, reps load in product to make their year end bonus! Q1 is always tough and I had heard from several reps that Q1 2024 was extremely slow.

Why would RVNC hire 20 plus people if they were not expecting therapeutic sales. I know Foley and Russell are idiots, but their jobs are now on the line as shareholders will vote them out! The therapeutic sales team only has 1 product..Daxi! 100% of their time is Daxi.

[iwfal]

That +7% QoQ is stellar! RHA sucked but that could be transitory as mentioned on the call.

1) Sure, but it came via, effectively, price cuts. Unit sales were up from Q4, $ down.

2) When asked to comment on data-seen-to-date in Q2 Foley put much more emphasis on RHA picking up, and just gave bland words on Daxxy early Q2 data. Its not clear they know how to get Daxxi into new accounts? Further he noted that the assumption for the predicted 2024 revenue of $280M is that more than half is RHA.. They're going to be more an RHA company in 2024 than a Daxxy company..